Epizyme, Inc. – NASDAQ:EPZM
Epizyme stock price today
$1.46
-0.01
-0.68%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 20 minutes
Epizyme stock price quarterly change
+214.30%
quarter
Epizyme stock price yearly change
-73.17%
year
Epizyme key metrics
Market Cap | N/A |
Enterprise value | 412.12M |
P/E | -0.70 |
EV/Sales | 7.77 |
EV/EBITDA | -2.31 |
Price/Sales | 4.63 |
Price/Book | -12.10 |
PEG ratio | 0.10 |
EPS | -1.76 |
Revenue | 53.00M |
EBITDA | -178.36M |
Income | -213.71M |
Revenue Q/Q | 111.59% |
Revenue Y/Y | 62.69% |
Profit margin | -391.89% |
Oper. margin | -370.05% |
Gross margin | 75.57% |
EBIT margin | -370.05% |
EBITDA margin | -336.48% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEpizyme stock price history
Epizyme stock forecast
Epizyme financial statements
| Sep 2021 | 5.20M | -65.83M | -1265.8% |
|---|---|---|---|
| Dec 2021 | 11.58M | -50.65M | -437.29% |
| Mar 2022 | 8.69M | -55.50M | -638.28% |
| Jun 2022 | 27.52M | -41.72M | -151.57% |
| 2021-11-09 | -0.45 | -0.64 |
|---|---|---|
| 2022-03-01 | -0.53 | -0.49 |
| 2022-05-10 | -0.35 | -0.38 |
| 2022-08-09 | -0.36 | -0.21 |
| Sep 2021 | 332271000 | 316.89M | 95.37% |
|---|---|---|---|
| Dec 2021 | 289000000 | 309.68M | 107.16% |
| Mar 2022 | 312186000 | 301.06M | 96.44% |
| Jun 2022 | 264159000 | 284.44M | 107.68% |
| Sep 2021 | -42.64M | 66.64M | 20.35M |
|---|---|---|---|
| Dec 2021 | -51.96M | 18.18M | 7.60M |
| Mar 2022 | -59.19M | -44.18M | 82.46M |
| Jun 2022 | -54.80M | 48.71M | -257K |
Epizyme alternative data
| Aug 2023 | 250 |
|---|---|
| Sep 2023 | 250 |
| Oct 2023 | 250 |
| Nov 2023 | 250 |
| Dec 2023 | 250 |
| Jan 2024 | 250 |
| Feb 2024 | 250 |
| Mar 2024 | 250 |
| Apr 2024 | 250 |
| May 2024 | 250 |
| Jun 2024 | 250 |
| Jul 2024 | 250 |
Epizyme other data
100.00%
+17.23%
of EPZM is owned by hedge funds
115
-16
143.93M
+59.08M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2021 | 0 | 1780 |
| Jan 2022 | 22666667 | 2922 |
| Feb 2022 | 0 | 7162 |
| Apr 2022 | 0 | 2741 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KUTOK JEFFERY officer: Chief Sc.. | Stock Option (Right to Buy) | 380,000 | $1.39 | $528,200 | ||
Option | KUTOK JEFFERY officer: Chief Sc.. | Common Stock, par value $0.0001 | 380,000 | $1.39 | $528,200 | ||
Option | BOGLE GRANT C. director, officer.. | Stock Option (Right to Buy) | 417,500 | $1.41 | $588,675 | ||
Option | BEAULIEU JOSEPH officer: Senior Vice President,.. | Stock Option (Right to Buy) | 300,000 | $1.39 | $417,000 | ||
Option | BEAULIEU JOSEPH officer: Senior Vice President,.. | Common Stock, par value $0.0001 | 300,000 | $1.39 | $417,000 | ||
Option | AGARWAL SHEFALI other | Stock Option (Right to Buy) | 400,000 | $1.39 | $556,000 | ||
Option | AGARWAL SHEFALI other | Stock Option (Right to Buy) | 43,473 | $1.39 | $60,427 | ||
Option | AGARWAL SHEFALI other | Stock Option (Right to Buy) | 56,527 | $1.39 | $78,573 | ||
Option | AGARWAL SHEFALI other | Common Stock, par value $0.0001 | 400,000 | $1.39 | $556,000 | ||
Option | BOGLE GRANT C. director, officer.. | Common Stock, par value $0.0001 | 417,500 | $1.41 | $588,675 |
| Patent |
|---|
Application Filling date: 23 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 23 Dec 2021 Issue date: 1 Sep 2022 |
Application Filling date: 29 Nov 2017 Issue date: 25 Aug 2022 |
Application Filling date: 15 Nov 2021 Issue date: 28 Jul 2022 |
Application Filling date: 23 Nov 2021 Issue date: 21 Jul 2022 |
Application Filling date: 21 Dec 2021 Issue date: 14 Jul 2022 |
Grant Filling date: 5 Aug 2020 Issue date: 28 Jun 2022 |
Application Filling date: 9 Dec 2021 Issue date: 23 Jun 2022 |
Application Filling date: 18 Nov 2021 Issue date: 9 Jun 2022 |
Application Filling date: 1 Nov 2021 Issue date: 26 May 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2022 10 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 1 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 9 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 9 Aug 2021 | Q2 2021 Earnings Call Transcript |
-
What's the price of Epizyme stock today?
One share of Epizyme stock can currently be purchased for approximately $1.46.
-
When is Epizyme's next earnings date?
Unfortunately, Epizyme's (EPZM) next earnings date is currently unknown.
-
Does Epizyme pay dividends?
No, Epizyme does not pay dividends.
-
What is Epizyme's stock symbol?
Epizyme, Inc. is traded on the NASDAQ under the ticker symbol "EPZM".
-
What is Epizyme's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Epizyme?
Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Epizyme's key executives?
Epizyme's management team includes the following people:
- Dr. Shefali Agarwal M.D., MPH Executive Vice President and Chief Medical & Devel. Officer(age: 51, pay: $684,960)
- Mr. Matthew E. Ros Advisor(age: 58, pay: $634,050)
- Dr. Jeffery L. Kutok Chief Scientific Officer(age: 58, pay: $563,980)
- Mr. Grant C. Bogle Pres, Chief Executive Officer, Principal Financial Officer & Director(age: 67, pay: $46,250)
-
How many employees does Epizyme have?
As Jul 2024, Epizyme employs 250 workers.
-
When Epizyme went public?
Epizyme, Inc. is publicly traded company for more then 12 years since IPO on 31 May 2013.
-
What is Epizyme's official website?
The official website for Epizyme is epizyme.com.
-
Where are Epizyme's headquarters?
Epizyme is headquartered at 400 Technology Sq Ste 4, Cambridge, MASSACHUSETTS.
-
How can i contact Epizyme?
Epizyme's mailing address is 400 Technology Sq Ste 4, Cambridge, MASSACHUSETTS and company can be reached via phone at +1 617 229 5872.
Epizyme company profile:
Epizyme, Inc.
epizyme.comExchange:
NASDAQ
Full time employees:
250
Industry:
Biotechnology
Sector:
Healthcare
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
400 Technology Sq Ste 4
Cambridge, MASSACHUSETTS 02139
Cambridge, MASSACHUSETTS 02139
CIK: 0001571498
ISIN: US29428V1044
CUSIP: 29428V104
